IL151014A0 - Partial fatty acid oxidation inhibitors in the treatment of congestive heart failure - Google Patents

Partial fatty acid oxidation inhibitors in the treatment of congestive heart failure

Info

Publication number
IL151014A0
IL151014A0 IL15101401A IL15101401A IL151014A0 IL 151014 A0 IL151014 A0 IL 151014A0 IL 15101401 A IL15101401 A IL 15101401A IL 15101401 A IL15101401 A IL 15101401A IL 151014 A0 IL151014 A0 IL 151014A0
Authority
IL
Israel
Prior art keywords
treatment
fatty acid
heart failure
congestive heart
acid oxidation
Prior art date
Application number
IL15101401A
Other languages
English (en)
Original Assignee
Cv Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cv Therapeutics Inc filed Critical Cv Therapeutics Inc
Publication of IL151014A0 publication Critical patent/IL151014A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL15101401A 2000-02-18 2001-02-15 Partial fatty acid oxidation inhibitors in the treatment of congestive heart failure IL151014A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US18356000P 2000-02-18 2000-02-18
US21990800P 2000-07-21 2000-07-21
PCT/US2001/004887 WO2001060348A2 (en) 2000-02-18 2001-02-15 Partial fatty acid oxidation inhibitors in the treatment of congestive heart failure

Publications (1)

Publication Number Publication Date
IL151014A0 true IL151014A0 (en) 2003-02-12

Family

ID=26879274

Family Applications (1)

Application Number Title Priority Date Filing Date
IL15101401A IL151014A0 (en) 2000-02-18 2001-02-15 Partial fatty acid oxidation inhibitors in the treatment of congestive heart failure

Country Status (17)

Country Link
US (2) US6528511B2 (pt)
EP (2) EP2033633A3 (pt)
JP (1) JP2004505886A (pt)
KR (1) KR20020075801A (pt)
CN (1) CN1227004C (pt)
AR (1) AR033510A1 (pt)
AU (1) AU778203B2 (pt)
BR (1) BR0108452A (pt)
CA (1) CA2398691A1 (pt)
HK (1) HK1048250A1 (pt)
IL (1) IL151014A0 (pt)
MX (1) MXPA02007639A (pt)
NO (1) NO20023879L (pt)
NZ (1) NZ520780A (pt)
TW (1) TWI235655B (pt)
WO (1) WO2001060348A2 (pt)
ZA (1) ZA200206451B (pt)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU778203B2 (en) * 2000-02-18 2004-11-25 Gilead Sciences, Inc. Partial fatty acid oxidation inhibitors in the treatment of congestive heart failure
WO2003037323A2 (en) * 2001-10-26 2003-05-08 MEDIGENE AG Gesellschaft für Molekularbiologische Kardiologie und Onkologie Inhibitors of the fatty acid oxidation for prophylaxis and treatment of diseases related to mitochondrial dysfunction
DE60221287T4 (de) * 2001-11-08 2009-06-25 Atrium Medical Corp. Intraluminale vorrichtung mit einer ein therapeutisches-mittel enthaltenden beschichtung
US20030220344A1 (en) * 2002-04-04 2003-11-27 Luiz Belardinelli Method of treating arrhythmias
US8822473B2 (en) * 2002-05-21 2014-09-02 Gilead Sciences, Inc. Method of treating diabetes
MXPA04011530A (es) * 2002-05-21 2005-08-15 Cv Therapeutics Inc Administracion de un inhibidor de acido graso parcial tal como ranolazina para el tratamiento de diabetes.
DE60314662T2 (de) * 2002-12-05 2008-03-13 CV Therapeutics, Inc., Palo Alto Substituierte piperazinverbindungen und deren verwendung als fettsäureoxidationsinhibitoren
EP1723129A1 (en) * 2003-12-18 2006-11-22 Cv Therapeutics, Inc. 1-akan-2-ol substituted piperazine and piperidine compounds
EP2298863B1 (en) † 2004-03-22 2015-07-22 Mesoblast International Sàrl Mesenchymal stem cells and uses therefor
US9801982B2 (en) * 2004-09-28 2017-10-31 Atrium Medical Corporation Implantable barrier device
US9012506B2 (en) * 2004-09-28 2015-04-21 Atrium Medical Corporation Cross-linked fatty acid-based biomaterials
US9000040B2 (en) 2004-09-28 2015-04-07 Atrium Medical Corporation Cross-linked fatty acid-based biomaterials
US20090011116A1 (en) * 2004-09-28 2009-01-08 Atrium Medical Corporation Reducing template with coating receptacle containing a medical device to be coated
US8367099B2 (en) * 2004-09-28 2013-02-05 Atrium Medical Corporation Perforated fatty acid films
EP1804717A4 (en) 2004-09-28 2015-11-18 Atrium Medical Corp DRUG DELIVERY COATING WHICH CAN BE USED WITH VASCULAR ENDOPROSTHESIS
US8312836B2 (en) 2004-09-28 2012-11-20 Atrium Medical Corporation Method and apparatus for application of a fresh coating on a medical device
US20060067976A1 (en) 2004-09-28 2006-03-30 Atrium Medical Corporation Formation of barrier layer
WO2006036970A2 (en) * 2004-09-28 2006-04-06 Atrium Medical Corporation Method of thickening a coating using a drug
BRPI0517650A (pt) * 2004-11-09 2008-10-14 Cv Therapeutics Inc uso de ranolazina em combinação com pelo menos um agente de remodelamento para reversão de remodelamento ventricular esquerdo no tratamento de insuficiência cardìaca
EP1865945A4 (en) * 2005-03-11 2008-05-21 Hong Kong Nitric Oxide Ltd TREATMENT COMBINATION FOR ENDOTHELIAL DISORDERS, ANGINA AND DIABETES
US9278161B2 (en) 2005-09-28 2016-03-08 Atrium Medical Corporation Tissue-separating fatty acid adhesion barrier
US9427423B2 (en) 2009-03-10 2016-08-30 Atrium Medical Corporation Fatty-acid based particles
CA2626030A1 (en) 2005-10-15 2007-04-26 Atrium Medical Corporation Hydrophobic cross-linked gels for bioabsorbable drug carrier coatings
US7606617B2 (en) * 2006-01-31 2009-10-20 Cardiac Pacemakers, Inc. Urinalysis for the early detection of and recovery from worsening heart failure
US7875017B2 (en) * 2007-04-11 2011-01-25 Henry Ford Health System Cardiac repair, resizing and reshaping using the venous system of the heart
WO2008030581A1 (en) * 2006-09-08 2008-03-13 Symphony Medical, Inc. Intramyocardial patterning for treating localized anomalies of the heart
US9492596B2 (en) * 2006-11-06 2016-11-15 Atrium Medical Corporation Barrier layer with underlying medical device and one or more reinforcing support structures
WO2008057344A2 (en) * 2006-11-06 2008-05-15 Atrium Medical Corporation Coated surgical mesh
US20090111826A1 (en) * 2007-02-13 2009-04-30 Louis Lange Use of ranolazine for the treatment of cardiovascular diseases
US20080193530A1 (en) * 2007-02-13 2008-08-14 Brent Blackburn Use of ranolazine for the treatment of non-coronary microvascular diseases
WO2008118552A1 (en) * 2007-02-13 2008-10-02 Cv Therapeutics, Inc. Use of ranolazine for the treatment of cardiovascular diseases
EP2117549A1 (en) * 2007-02-13 2009-11-18 CV Therapeutics Inc. Use of ranolazine for the treatment of coronary microvascular diseases
US20080233191A1 (en) * 2007-03-22 2008-09-25 Brent Blackburn Use of ranolazine for elevated brain-type natriuretic peptide
EP2170333B1 (en) * 2007-05-31 2013-02-20 Gilead Sciences, Inc. Ranolazine for elevated brain-type natriuretic peptide
CN101066253B (zh) * 2007-06-07 2011-01-05 北京本草天源药物研究院 一种雷诺嗪缓释片
WO2008154033A2 (en) * 2007-06-11 2008-12-18 Symphony Medical, Inc. Cardiac patterning for improving diastolic function
US20090012103A1 (en) 2007-07-05 2009-01-08 Matthew Abelman Substituted heterocyclic compounds
WO2009100380A1 (en) * 2008-02-06 2009-08-13 Cv Therapeutics, Inc. Use of ranolazine for treating pain
AU2010248948A1 (en) * 2009-05-14 2011-12-01 Gilead Sciences, Inc. Ranolazine for the treatment of CNS disorders
US20110038910A1 (en) 2009-08-11 2011-02-17 Atrium Medical Corporation Anti-infective antimicrobial-containing biomaterials
EP2480234B1 (en) * 2009-09-25 2020-02-26 Lupin Limited Sustained release composition of ranolazine
WO2012009707A2 (en) 2010-07-16 2012-01-19 Atrium Medical Corporation Composition and methods for altering the rate of hydrolysis of cured oil-based materials
EP2524688B1 (en) * 2011-05-11 2013-05-01 ratiopharm GmbH Composition for modified release comprising ranolazine
US9867880B2 (en) 2012-06-13 2018-01-16 Atrium Medical Corporation Cured oil-hydrogel biomaterial compositions for controlled drug delivery
CN104758265B (zh) * 2014-01-07 2019-05-17 四川海思科制药有限公司 一种雷诺嗪缓释片药物组合物及其制备方法
FR3060567B1 (fr) 2016-12-19 2019-05-24 Ecole Normale Superieure De Lyon Substrat de glycosidase fluorogene et procede de detection associe
CN112438955A (zh) * 2019-08-30 2021-03-05 深圳翰宇药业股份有限公司 一种雷诺嗪缓释组合物及其制备方法
GR1010510B (el) * 2022-06-07 2023-07-20 Ελπεν Α.Ε. Φαρμακευτικη Βιομηχανια, Στερεες φαρμακοτεχνικες μορφες παρατεταμενης αποδεσμευσης ρανολαζινης

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US4326525A (en) 1980-10-14 1982-04-27 Alza Corporation Osmotic device that improves delivery properties of agent in situ
US4567264A (en) 1983-05-18 1986-01-28 Syntex (U.S.A.) Inc. Cardioselective aryloxy- and arylthio- hydroxypropylene-piperazinyl acetanilides which affect calcium entry
US5364620A (en) 1983-12-22 1994-11-15 Elan Corporation, Plc Controlled absorption diltiazem formulation for once daily administration
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US4992445A (en) 1987-06-12 1991-02-12 American Cyanamid Co. Transdermal delivery of pharmaceuticals
US5001139A (en) 1987-06-12 1991-03-19 American Cyanamid Company Enchancers for the transdermal flux of nivadipine
US4902514A (en) 1988-07-21 1990-02-20 Alza Corporation Dosage form for administering nilvadipine for treating cardiovascular symptoms
US5001193A (en) 1988-12-22 1991-03-19 American Cyanamid Epoxy adhesive for bonding of automotive parts made from bulk or sheet molding compound containing polymeric toughening agent and Mannich Base
NZ247044A (en) * 1989-06-23 1997-04-24 Syntex Usa Inc Substituted For Use of ranolazine and related piperazine derivatives to treat tissue affected by muscle and neuronal damage, including transplant tissue
US5455045A (en) 1993-05-13 1995-10-03 Syntex (U.S.A.) Inc. High dose formulations
US6083532A (en) * 1995-03-01 2000-07-04 Duramed Pharmaceuticals, Inc. Sustained release formulation containing three different types of polymers and tablet formed therefrom
US6303607B1 (en) * 1998-09-10 2001-10-16 Cv Therapeutics, Inc. Method for administering a sustained release ranolanolazine formulation
AU778203B2 (en) * 2000-02-18 2004-11-25 Gilead Sciences, Inc. Partial fatty acid oxidation inhibitors in the treatment of congestive heart failure
NZ520782A (en) * 2000-02-22 2004-03-26 Cv Therapeutics Inc Substituted piperazine compounds that are partial fatty acid oxidation inhibitors

Also Published As

Publication number Publication date
NZ520780A (en) 2006-04-28
EP1259230A2 (en) 2002-11-27
NO20023879D0 (no) 2002-08-15
WO2001060348A3 (en) 2002-01-31
MXPA02007639A (es) 2004-08-23
US6528511B2 (en) 2003-03-04
WO2001060348A2 (en) 2001-08-23
ZA200206451B (en) 2003-12-31
AU778203B2 (en) 2004-11-25
CN1420766A (zh) 2003-05-28
US20010047000A1 (en) 2001-11-29
NO20023879L (no) 2002-08-15
AR033510A1 (es) 2003-12-26
BR0108452A (pt) 2003-04-01
TWI235655B (en) 2005-07-11
JP2004505886A (ja) 2004-02-26
CA2398691A1 (en) 2001-08-23
EP2033633A3 (en) 2009-07-08
EP2033633A2 (en) 2009-03-11
US6677342B2 (en) 2004-01-13
HK1048250A1 (zh) 2003-03-28
CN1227004C (zh) 2005-11-16
KR20020075801A (ko) 2002-10-05
AU4150501A (en) 2001-08-27
US20030119718A1 (en) 2003-06-26

Similar Documents

Publication Publication Date Title
IL151014A0 (en) Partial fatty acid oxidation inhibitors in the treatment of congestive heart failure
HK1073441A1 (en) Administration of a partial fatty acid oxidation inhibitor such as ranolazine for the treatment of diabetes
AU8707601A (en) Heart support to prevent ventricular remodeling
EP1412023A4 (en) METHOD AND DEVICE IN-VIVO FOR IMPROVING THE DIASTOLIC FUNCTION OF THE LEFT VENTRICLE
AU2001249881A1 (en) Method of treating the heart
HUP0402629A3 (en) 17beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
ZA200107122B (en) Treatment of acne using lipoic acid.
HK1085615A1 (en) Fatty acid desaturases from fungi
HK1048443A1 (en) Fatty acid derivative for the treatment of external secretion disorders
LT1366018T (lt) (r)-2-arilpropiono rūgščių omega-amino alkilamidai kaip polimorfonuklearinių ir mononuklearinių ląstelių chemotaksio inhibitoriai
NO20031784D0 (no) Heteroarylalkylpiperazinderivater som fettsyre- oksydasjonsinhibitorer
PL362984A1 (en) Compounds useful in the treatment of inflammatory diseases
IL149251A0 (en) Diagnosis and treatment of cardiovascular conditions
IL154802A0 (en) New oxabispidine compound useful in the treatment of cardiac arrhythmias
HUP0301059A3 (en) Use of lactic acid bacterium for the treatment of peritonitis
EP1340740A4 (en) LIPID OF CARBOXYLIC ACID
GB0111594D0 (en) Pipecolnic acid derivatives method of manufacturing the same and therapeutic agents containing these compounds
AU8609201A (en) Reduction of the electrocardiographic ot interval
GB9907082D0 (en) The preparation of carboxylic acid derivatives
PL338405A1 (en) Method of obtaining 2-quinoxalincarboxylic acid
HU0000015V0 (en) Junction arrangement for treatment of acid accumulators
GB0018320D0 (en) Method of safely oxidizing fat molecules in vivo
EE04960B1 (et) Meetod arliminometlkarbamiinhappeestrite valmistamiseks
AU2001228481A1 (en) Oxidation of o-xylol to produce o-tolyl acid
SI1296670T1 (sl) Teraprvtske kombinacije mascobnih kislin